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Consequences of Antigenic Diversity of Bovine Viral Diarrhea Virus
E. Travis Llttledlke, Steven R. Bolin, and Julia F. Ridpath'"
Introduction
Two main biotypes of bovine viral diarrhea virus (BVDV)
have been identified based on their ability to cause changes
in tissue culture cells. The cytopathic biotype multiplies in
tissue culture and kills cells, while the noncytopathic biotype slowly multiplies in tissue culture and has much less
ability to kill tissue culture cells. In general, cytopathic
BVDV biotypes cause acute infections that often kill the
bovine fetus, while noncytopathic BVDV biotypes often
result in chronic infection of the fetus which, subsequently,
develops in calves and adults that carry and shed noncytopathic viruses at high levels for the rest of their lives.
Previous studies have indicated that cytopathic and noncytopathic viruses are antigenically similar. Also, after vaccination of cattle with modified-live or killed BVDV vaccines,
antibodies are induced that neutralize a broad range of
BVDV. However, very significant antigenic diversity among
BVDV has been described.
Also, studies indicated that
some neutralizing antibodies from cattle that have recovered from BVDV react differently with several BVD isolates.
In addition, monoclonal antibodies developed against specific BVDV isolates can differentiate
BVDV into several
groups and, when cattle which are persistently infected with
noncytopathic BVDV are challenged with cytopathic BVDV,
the antibodies they produce have a very narrow range of
viral neutralizing activity.
Thus, some antigenic diversity among BVDV, as detected
by neutralization tests, is well established.
However, there
is little information that shows the practical consequences of
this antigenic diversity relative to the disease in cattle.
The primary purpose of this study was to identify cattle in
MARC's herd that were persistently infected with BVDV and
test the isolates of BVDV from the MARC herd to determine
if these natural field viruses could be neutralized by serum
obtained from MARC cows vaccinated with killed BVDV.

Procedure
Source of sera.

Serum was obtained over a 5-wk period

in the fall of 1988 from 5,726 cows maintained as a semiclosed herd on pasture. At that time, the herd had been on
a killed virus vaccination program for BVD for more than 7
years. The vaccine used was of bovine-cell origin and contained the Singer isolate of cytopathic BVDV. The vaccination program consisted of calfhood vaccination with the first
dose given 1 mo before weaning and the second dose
given 4 wk later at the time of weaning. Thereafter, cows
were revaccinated with a single dose of vaccine 2 to 3 wk
before breeding. Approximately, 80% of cows calved in
April and May and the remaining 20% calved in August and
September. At the time samples of serum were obtained,
cows calving in the spring were at approximately 3 mo of
gestation and had been vaccinated approximately 4 mo previously. Cows that calved in the late summer had calved
approximately 2 mo previously and were vaccinated
approximately 12 mo previously. The herd was managed
as several groups of varying numbers maintained on sepa-
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rate pastures.
At weaning, calves from all groups were
moved to a feedlot. Performance of a calf in the feedlot was
one of the criteria used to select herd replacements and cull
dams. The replacement rate for the herd was approximately 20% per year.
Viral neutralization tests. Sera were tested for neutralizing antibodies against one or more of the following viruses:
cytopathic viral isolates BVD-TGAC and BVD-Singer, and
noncytopathic viral isolates BVD-3659, BVD-2541, BVD9789, BVD-NEB,
BVD-7443,
BVD-639, and BVD-VM.
Noncytopathic viruses 9789, NEB, 7443, and VM were isolated from persistently infected cattle, BVD-639 was isolated
from the uterus of a cow that aborted, and BVD-3659 and
BVD-2541 were isolated from persistently infected cattle
identified during this study. With the exception of BVD-3659
and BVD-2541, the viruses used were antigenically distinct
from each other when tested against a panel of monoclonal
antibodies that had neutralizing activities. Viruses 3659 and
2541 were antigenically similar to each other, but distinct
from the other viruses.
Neutralization tests against BVD-TGAC virus were performed on all samples of serum. Those samples of serum
that had neutralized antibody titers of less than 2, 2, 4, or 8
were tested for neutralizing antibody titer against BVDSinger virus. In addition, 18 selected samples of serum that
had neutralized antibody titers of less than 2, 2, or 4 against
BVD- TGAC virus were tested for neutralizing antibodies
against the aforementioned
seven noncytopathic
BVD
viruses. All samples of serum (n=56) that had neutralized
antibody titers of eight against BVD- TGAC virus were tested
for neutralizing antibodies against noncytopathic BVD-3659
virus.
Immunoprecipitation.
In selected samples of serum from
killed virus vaccinates that had neutralized antibody titers of
less than 2 to 256 against BVD- TGAC virus, antibody specificity for polypeptides induced by BVD-Singer virus (vaccine
virus) was identified by immunoprecipitation.
For comparison, viral induced polypeptides were immunoprecipitated
with samples of serum obtained from modified-live virus
vaccinates that had neutralizing titers of 2 to 16 against
BVD- TGAC virus.

Results
Virus was isolated from 3 of 448 samples of serum that
had neutralized antibody titers of 64 or less against BVDTGAC virus (Table 1). In those three samples of serum, the
neutralizing antibody titers against BVD-TGAC virus were
less than 2, 2, and 32. The corresponding neutralizing antibody titers against BVD-Singer virus were 32, 64, and 256.
Persistent infection was subsequently confirmed in two
cows (ages 2 and 3 yr) by isolation of virus (designated
BVD-3659 and BVD-2541) from a second sample of serum
obtained at least 4 wk before or after the original sample of
serum. Due to poor performance, a third cow (2 yr of age)
had been sold soon after the original sample of serum was
obtained. It was not possible to confirm persistent infection
in that cow. Virus was not isolated from sera obtained from
siblings of one persistently infected cow or the dam of the
other persistently infected cow.
Neutralizing antibody titers of four or less against BVDTGAC virus were detected in samples of serum obtained

from 91 and 40 cows that calved in the fall and spring,
respectively. In each of those 131 samples of serum, neutralizing antibody titers against BVD-Singer virus were
greater than the corresponding neutralizing antibody titers
against BVD-TGAC virus (Table 1). From those 131 samples of serum, 18 were selected and further tested for neutralizing antibodies against seven noncytopathic BVD
viruses. None of these 18 samples of serum contained
neutralizing antibodies against all seven noncytopathic
viruses (Table 2). Noncytopathic BVD-3659 virus was not
neutralized by any of the selected samples of serum. The
BVD-3659 virus was neutralized by 18 of 56 samples of
serum that had neutralized antibody titers of eight against
BVD-TGAC virus (data not shown).

Conclusion
Although the herd surveyed in this study had been on a
killed BVDV vaccination program for 7 yr, two persistently
infected cows were identified. Persistent BVDV infection is
lifelong and occurs in calves born to dams that have an
acute, transient viral infection during the first 4 mo of gestation or to dams that are themselves persistently infected.
The two persistently infected cows likely represented failure
of vaccination to protect against fetal infection under natural
conditions. That finding supported previous studies in
which experimental, killed BVDV vaccines failed to prevent
transplacental transmission of virus in challenged, exposed
cows.
Failure of vaccination to protect the fetus might be
explained by antigenic differences among BVD viruses. In
several sera from this herd, the titer of neutralizing antibodies against the vaccine virus was relatively high (64 to 256);
however, several isolates of BVD virus were identified that
escaped neutralization by those same sera. Those data
clearly indicate antigenic diversity among BVD viruses.
Included among the viruses that escaped neutralization were
noncytopathic viruses BVD-3659 and BVD-2541 that were
isolated from persistently infected cows in this herd. Thus,
the persistently infected cows likely represented a practical
consequence of antigenic diversity among BVD viruses.
Natural decay of viral-specific antibody likely contributed
to the lack of detectable antibodies against certain BVD
viruses. Data from this study support this hypothesis.
Approximately, 80% of the cows were given a booster dose
of vaccine 4 mo before samples of sera were obtained and
the remaining 20% of cows were boostered with vaccine 12
mo before sampling. A disproportionately high 91 of 131
samples of serum (70%) that had neutralizing antibody titers
of four or less against BVD-TGAC virus were obtained from
cows vaccinated 12 mo before sampling. Thus, failure to
detect neutralizing antibodies against certain BVD viruses
several mo after vaccination may have been attributable to
viral antigenic diversity and natural decay of antibodies.

On the basis of the large number of samples of sera that
had high titers of neutralizing antibodies against a BVD
virus antigenically distinct from the killed vaccine virus, and
on the pattern of immunoprecipitated viral-induced polypeptides associated with those sera, we speculate that most of
the cattle in this herd had been infected with BVD virus.
Identification of only two persistently infected cows might
seem trivial; however, the rate of persistent infection probably would have been higher if newborn calves were tested
instead of cows. Subsequent to completion of this study,
eight calves in this herd (approximately 2 yr old) were identified as persistently infected with BVD virus. The persistently infected cattle in this herd likely were born to vaccinated cows that were infected with field virus during early
gestation. Consequences of antigenic diversity among BVD
viruses are not likely limited to fetal infections in vaccinated
dams. Newborn calves with colostral antibody or vaccinated feedlot calves might be susceptible to disease
induced by certain antigenic variants of BVD virus.

Table 1-Dlstrlbutlon of neutralizing antibody titers
(-log2) against bovine viral diarrhea (BVD)-TGAC
virus In all samples of serum and range of titers and
geometric mean titers of neutralizing antibodies
against BVD-Slnger virus In samples of serum that
had neutralized antibody titers of three (-log2) or less
against BVD-TGACvirus
Geometric mean

Number Neutralizing antibody
of sera
titer to TGAC virus
48
42
41
56
61
70
130
253
5,025

.

0
1
2
3
4
5
6
7
8

Singer virus

Range of neutralizing
antibody titers to
Singer virus

4.09
5.25
6.11
5.21
ND
ND
ND
ND
ND

1 to 8
3 to 8
3 to 8
3 to 8
ND
ND
ND
ND
ND

titersto

ND Notdone.
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Table 2-Neutrallzlng antibody titers (-log2) In select sera against bovine viral diarrhea (BVD)-TGACvirus, corresponding titers of neutralizing antibodies against BVD-Slnger virus, and presence (+) or absence (-) of detectable
concentrations of neutralizing antibodies against seven antlgenlcally distinct noncytopathlc BVDviruses
Neutralizing
antibody titer

TGAC
virus

Singer
virus

Neutralizing activity against
noncytopathic viruses.
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Serum was diluted 1:1 wi1hfluid con1aining virus.

b Viral isola1es from MARC herd.
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